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ABSTRACT
Kabir, Mohammad. M.S. The University of Memphis. August 2012. Effects of a 21 Day
Simvastatin Treatment on Exercise Performance in Male Sprague Dawley Rats. Major
Professor: Zsolt Murlasits, Ph.D.
Statin treatment for high cholesterol has been shown to have many beneficial
effects. However, some studies have shown that statin treatment can potentially have
adverse physiological effects. We looked at the effects of a 21-day statin treatment on
exercise performance in male Sprague Dawley rats. The rats were consistently trained
for 12 days and performed a maximal exercise test on the final day of the study. Time to
exhaustion was used as the primary performance marker and we noted a difference
between the statin group and placebo group (P<0.05). The average time to exhaustion
was 36.05 min for the statin group and 37.64 for the placebo group. Masses of the heart,
soleus, and gastrocnemius muscles did not differ between the statin and placebo groups.
Blood samples showed a 17% lower cholesterol level in the statin group compared to the
placebo group.
Key words: statins, performance, exercise, cholesterol, Sprague dawley
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PREFACE
This thesis was written in article format for submission to the journal, Medicine &
Science in Sports & Exercise. The content and organization of this thesis represent and
fulfill the requirements for submission to this journal.
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INTRODUCTION
Statins, also known as 3-Hydroxy-3-methylglutaryl coenzyme A (HMG-CoA)
reductase inhibitors, are a class of cholesterol-lowering drugs. Statins have been shown
to be very effective in reducing elevated levels of serum cholesterol (35) and are well
tolerated by humans (35). Due to their effectiveness and tolerance, statins are widely
used all over the world. As a matter of fact, more than 100 million prescriptions were
filled for over 14 million patients in the year 2004 alone (15). According to a U.S.
medical expenditure panel survey in 2008, the number of people purchasing statins
almost doubled from 15.8 million in the year 2000 to 29.7 million by the year 2005 (49).
In the year 2011, statin prescriptions totaled almost one million in the United Kingdom
on a weekly basis (59). It is evident that statins have become the primary choice of
cholesterol lowering drugs for many patients and their physicians.
Statins work by acting as inhibitors of the cholesterol synthesis pathway, by
specifically competing with HMG-CoA for the catalytic site of its reductase (39). As a
result, a competitive inhibition occurs in the mevalonate pathway, a precursor molecule
for the synthesis of cholesterol and various other molecules (39), leading to decreased
cholesterol synthesis within the whole body. Statin treatment also has the potential to
produce adverse effects. These include skeletal muscle myopathy, which can range from
mild complaints such as weakness and myalgia. More serious adverse reactions include
rhabdomyolysis and renal failure in approximately 1-7% of the treated patients, which
does not correlate with the cholesterol lowering action of the drug (47, 48). Such
complications can possibly lead to statin therapy or exercise non-compliance (55). The
exact mechanism of statin-induced myalgia is not well understood (6); however, this can
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possibly occur as a result of the effect on the muscle fiber indirectly due to the reduction
of cholesterol synthesis. Membrane fluidity can be affected due to altered
cholesterol/phospholipid ratio (62, 63). Furthermore, statin administration may lead to
mitochondrial dysfunction or apoptosis in myocytes (4, 52).
Studies have shown that the prevalence of myopathy increases drastically among
statin users who also exercise (57) and such trends suggest that muscle performance may
be affected. This unique issue presents a contradiction, as it is in the best interest of the
statin user to maximize the benefits of both statin and exercise (35). Furthermore, the
effects of exercise and performance among statin users have not been carefully examined
according to Thompson et al. (55). Muscle performance is an important aspect of quality
of life and it is essential for optimal physiology and health, especially among individuals
who want to maintain a physically active lifestyle. Exercise has been shown to have
many healthy benefits (32), and play a significant role in decreasing the incidence of
mortality from cardiovascular disease (38). Therefore, it is important to confirm that
statin drugs, which are prescribed to enhance cardiovascular health, can do so without
adversely altering physical function.
The purpose of this study was to examine the effects of Simvastatin therapy (a
commonly prescribed statin drug) on exercise performance using an animal model, with
the goal of providing a foundation for future research using human subjects. The
working hypothesis is that Simvastatin treatment negatively impacts exercise
performance (i.e, endurance capacity), as measured by running time-to-exhaustion.
Additional outcome measures included serum cholesterol and muscle weights.
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METHODS
Animals
Twenty-four healthy, male Sprague-Dawley rats, roughly 14-16 weeks old and
weighing between 225-250 grams, were obtained from Harlan Laboratories (Indianapolis,
IN) through the University of Memphis animal care facility. All rats were free of any
cardiovascular, metabolic, or pulmonary diseases and all procedures were performed in
accordance with the animal care guidelines and approved by the Institutional Animal
Care and Use Committee at the University of Memphis. The rats were individually
housed in standard plastic shoe box cages in temperature controlled (18°-21°C) and
humidity controlled (RHR 50%-65%) environment with a reverse 12-hour light/dark
cycle, where the lights were automatically switched on at 10pm and switched off at 10am
for the duration of the study. The rats were acclimated to laboratory conditions for three
days prior to the beginning of study. During and after the acclimation period the rats
were fed a standard laboratory chow and water ad libitum. The rats were divided into
two groups: Statin group and Placebo group. Each group consisted of 6 rats that were
assigned randomly to statin and control treatments.
Statin: Dosage and administration
A powdered form of Simvastatin® (3-Hydroxy-3-methylglutaryl coenzyme A
reductase inhibitor) was obtained from Toronto Research Chemicals (North York, ON).
Canned sweet potatoes (Kroger, Cincinnati, OH) were used as the vehicle for
administration of the dose after establishing it was well accepted by the rats. Statin
dosage was matched to body-weight and the statin treatment groups received a dosage of
10 mg/kg/day. The statin dosage was mixed with 20-30 grams of sweet potato and rolled
3

into a capsule shape and placed on the feeder. The placebo group received the sweet
potato vehicle only, without statin. The statin/placebo groups were fed every night
between 8:00pm and 9:00pm. The rat chow was removed to ensure consumption of the
statin/placebo vehicle. Animal care technicians were advised not to feed the rats if any
sweet potato remained visible on the feeder in the morning. The treatment period lasted
for a total of 21 days, including the night before the animals were euthanized for
collection of samples. The study timeline is presented in Table 1.
Exercise Protocol
Familiarization and Training
Animals in both groups were acclimated to Exer 3R rodent treadmills (Columbus
Instruments, Columbus, OH) for three days prior to initiation of study. Familiarization
consisted of running at speeds of 10 m/s to 15 m/s for 10 minutes on day 1, 15 m/s to 20
m/s for 15 minutes on day 2, and 15 m/s to 25 m/s for 20 minutes on day 3. Upon
completion of familiarization, rats were trained at a speed of 25 m/s for 30 minutes a day
for a total of 12 days, which was considered to be representative of moderate intensity
similar to protocols described by Hildebrandt and Mitchell (25, 36). Prior to a training
session, the rats were given a warm-up session which consisted of running between 18
m/s to 22 m/s for a few minutes and the speed was gradually increased to 25 m/s.
Automated shocks were delivered if the rats did not maintain the prescribed speed for the
30 min period. Animals that exhibited difficulty in running were removed promptly from
the treadmill and dropped from the study based on further observations.
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Exercise Testing
All animals performed a maximal exercise test on the final day of the study, one
day prior to necropsy. The exercise testing consisted of a 3 minute warm-up when the
rats ran at a speed of 15 m/s for the first minute, 20 m/s for the second minute, and 25 m/s
for the third minute. As soon as the warm-up period was concluded, a timer was started
and the speed was increased 1 m/s after every 2 minutes until the rats were exhausted,
based on receiving 3 or more shocks within a 10 second time frame. Time to exhaustion
was recorded at the conclusion of exercise testing for each animal. Further observations
were made at necropsy to ensure they were still healthy.
Clinical Chemistry
Necropsy and Tissue Collection
The day following the exercise testing (approximately 12 hrs post-exercise test),
animals were euthanized individually using CO₂ inhalation in a gas chamber. Blood
samples (volume) were collected via cardiac puncture from all animals into Vacutainer®
tubes and allowed to clot at room temperature before centrifugation (1500 rpm for 15
minutes at 4°C). The serum was removed and stored (-70° C) for later analysis. All
animals were weighed prior to necropsy and the heart, soleus muscle (right and left) and
gastrocnemius muscle (right and left) were harvested, weighed, and stored for future
analysis. With the exception of blood samples for measurement of cholesterol and tissue
samples for measure of weights, it should be noted that these samples were not used for
any outcome measures in the current study.
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Biochemistry
Total serum cholesterol was analyzed using a commercially available colorimetric
assay kit (BioVision, Mountain View, CA). Following the supplier’s instructions, serum
samples were diluted 10-fold using the cholesterol assay buffer. The reaction mixture
was prepared using a combination of cholesterol assay buffer, cholesterol probe, enzyme
mix and esterase. The reaction mixture was transferred to respective microplate wells
and the absorbance was read using a spectrophotometer at 570 nm. A calibration curve
using cholesterol standard buffer in various dilutions was prepared. Total cholesterol was
calculated using the absorbance at 570 nm and the quantification was performed using
the equation C=A/V, where A stood for the amount of cholesterol determined from
standard curve and V stood for the volume of sample added into the reaction well.
Statistical Analysis
The data were analyzed using a one-way ANOVA and t-test. Comparisons were
analyzed for time to exhaustion, weights, and cholesterol levels between the statin group
and placebo group. All analyses were performed using SPSS statistical software
(Somers, NY). Statistical significance was set at P ≤ 0.05 and the data are presented as
mean ± SEM.
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RESULTS
Out of 24 animals, 17 successfully completed the study (8 in the statin group and
9 in the placebo group. Two rats (one in each group) were unable to run on the treadmill
properly, two rats (one in each group) were unable to successfully complete the maximal
exercise test, two rats (one in each group) were dropped as outliers, and one rat (statin
group) was dropped due to prematurely stopping the treadmill before the exhaustion
criteria was met during the maximal exercise test.
Weight measurements, which included total body weight and masses of the heart,
right and left soleus muscle, and right and left gastrocnemius muscle are presented in
Table 2. Due to improper necropsy procedure, the weight of 2 gastrocnemius muscles
from the first two animals from the statin group was dropped. Mean body weight for the
statin group (306.19±3.43g) tended to be lower than the placebo group (312.34±7.98g).
The mean weight for the heart was 1.00±.025g for the statin group and 1.06±.024g for the
placebo group with no significant difference (P=0.12). The mean weights of right and
left gastrocnemius muscles for the statin group was 2.046±0.023g and 2.036±0.032g
respectively, and for the placebo group it was 2.071±0.044g and 2.048±0.043g
respectively, with no significance (P > 0.05). Although it was not significant, a trend was
noted between the statin group and placebo group for the right and left soleus muscles.
A difference was noted for time to exhaustion between the statin and placebo
groups (P < 0.05), where the average time to exhaustion was 36.05±0.44 min for the
statin group and 37.64±0.38 min for the placebo group (mean difference of 1.59; ~4%
lower for statin group) with a standard deviation of 1.249 and 1.133 respectively for each
group. A difference was also noted between total cholesterol levels (P = 0.04) between
7

the groups with an average of 73.17±5.31 mg/dl for the statin group and 87.84±4.30
mg/dl for the placebo group. Time to exhaustion values are presented in Table 3 and
cholesterol values are presented on Table 4.
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DISCUSSION
This study investigated the effects of a 21 day statin treatment on exercise
performance in young male rats. Although there has been a recent surge in studies
involving statins, the effects of statin on exercise performance has not been carefully
examined and to our knowledge, no study to date has used time to exhaustion and
muscle/tissue weights markers of performance, particularly with Sprague Dawley rats
using Simvastatin treatment. The main findings from this investigation were (a) Shortterm, high dosage statin treatment with moderate exercise training does not significantly
alter total body weight, heart weight, and gastrocnemius muscle weight; (b) Short-term
high dosage statin treatment with moderate exercise training could potentially affect
soleus muscle performance; (c) High dosage statin treatment in addition to moderate
exercise training has the potential to negatively affect exercise performance, as indicated
by run time to exhaustion.
All animals that completed the study successfully were considered healthy during
time of necropsy. Animals were exercise-trained (as it can be viewed in Table 1) with
each group receiving either a statin or placebo treatment. According to expectations,
there was a significant difference in cholesterol levels between the two groups, with the
statin group having 17% lower values compared to the placebo group (73.17±5.31 mg/dl
vs. 87.84±4.30 mg/dl). The lack of differences for body weight and weights of the
heart, and gastrocnemius muscles contrast with previous reports using a different model
have shown to induce rhabdomyolysis (8, 24, 44). However, this was not the case in our
study as we did not see any significant differences in each of those respective criteria
within the two groups.
9

It was interesting, however, to notice a trend in the weights of the soleus muscle
between the two treatment groups. Although it is not significant, there was a slight
difference (P=0.07) and (P=0.06) respectively for right and left soleus for the two
groups. While the reasons for this tendency remain uncertain, there is a possibility that
the responses to statin therapy differ among types of muscle fibers. According to Ariano
et al, the soleus muscle among Sprague Dawley rats has the highest proportion of slowoxidative fibers (1) and the composition of the soleus muscle can vary based on the type
of species. Future studies examining the effects of statin and exercise on various muscle
types (slow-oxidative vs. fast-oxidative/glycolytic) would reveal a more definite
explanation.
It is also interesting to note that there was a difference in time to exhaustion
between the two groups in our study. The average time to exhaustion was 36.05±0.44 for
the statin group and 37.64±0.38 for the placebo group (P=0.014). This suggests that
exercise performance can be affected by statin treatment. However, a future study
involving a larger sample size is needed as we had a large standard deviation for our
relatively small sample size of N=24.
There could be a number of reasons for this difference. As suggested by previous
reports, the slight decline in performance can be possibly due to myopathy (35) or even
apoptosis due to toxicity (28). Additionally, reduced cholesterol synthesis due to statins
can affect membrane fluidity (63), which can compromise mitochondrial structure and
affect the electron transport chain functions. As a result, it is theoretically possible that
aerobic capacity will be decreased by statin therapy. However, a study performed by
Traustadottir et al. suggests that high dose statin treatment does not impair aerobic
10

capacity or skeletal muscle function (58). Furthermore, it is possible that an intermediary
protein or a precursor molecule such as Q10 can be responsible. By acting as inhibitors
of HMG-CoA, statins interfere with the production mevalonic acid, which is a precursor
of COQ10 (14). COQ10 is an important component of the electron transport chain and
its deficiency or absence can certainly affect cellular respiration and ATP generation. A
recent study suggests that this may actually be the case (40), however long-term studies
using human models are needed to confirm the underlying cause of decline of exercise
performance due to statin therapy.
Although this study was conducted in a controlled manner for the most part, there
were several limitations. The sample size was relatively small as 17 out of the 24
animals were able to successfully complete the study. As a result, the standard deviation
was somewhat large for some variables. Additionally, instead of using a gavage, a
vehicle in the form of sweet potato was used in order to reduce the stress levels on the
animals. Although every effort was made to ensure that the rats consumed the treatment
vehicle (as confirmed by cholesterol level data), there is a chance that 100% of the
vehicle was not consumed by every rat. It was also difficult to obtain a blood sample
post-exercise test for secondary performance measures.
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CONCLUSION
High dosage Simvastatin treatment has the potential to compromise exercise
performance as measured by time to exhaustion. This may be partly explained by a
decrease in cholesterol content, reduction of other precursor molecules, or myopathy of
certain muscle fiber types. These findings are specific to a sample of newly exercisetrained male Sprague Dawley rats. Future work is necessary to investigate the effects of
muscle fibers (slow vs. fast, oxidative vs. glycolytic) and precursor molecules of the
mevalonate pathway such as protein content, COQ10, or mitochondrion functionality.
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APPENDIX A – TABLES AND FIGURES

Table 1. Study timeline
Day
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25

Activity
Acclimation
Acclimation
Acclimation
Treatment day 1
Treatment day 2
Treatment day 3
Treatment day 4
Treatment day 5/Familiarization day 1
Treatment day 6/Familiarization day 2
Treatment day 7/Familiarization day 3
Treatment day 8/Training day 1
Treatment day 9/Training day 2
Treatment day 10/Training day 3
Treatment day 11/Training day 4
Treatment day 12/Training day 5
Treatment day 13/Training day 6
Treatment day 14
Treatment day 15/Training day 7
Treatment day 16/Training day 8
Treatment day 17/Training day 9
Treatment day 18/Training day 10
Treatment day 19/Training day 11
Treatment day 20/Training day 12
Treatment day 21/Max. Exercise Test
Necropsy

*Animals were randomly assigned to either statin group or placebo group
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Table 2. Body weight, heart weight, right and left soleus weight, and right and left
gastrocnemius weight present in grams (g) as well as the P-values for statistical
significance of the N=17 rats that successfully completed the study. Values are means
and SEM.
Muscle/Organ

Statin Group (N=8)

Placebo Group (N=9)

P-Value

Body

306.19 ± 3.43

312.34 ± 7.98

0.51

Heart

1.00 ± 0.025

1.06 ± 0.024

0.12

Right Soleus

0.125 ± 0.003

0.133 ± 0.003

0.07

Left Soleus
*Right
Gastrocnemius

0.127 ± 0.003

0.134 ± 0.003

0.06

2.046 ± 0.023

2.071 ± 0.044

0.67

*Left Gastrocnemius

2.036 ± 0.032

2.048 ± 0.043

0.84

*Values of the weight of 2 gastrocnemius muscles from the first two animals from the
statin group were dropped due to procedural error; sample size set to N=6 for statin
group.

Table 3. Time to exhaustion data presented for both statin and placebo groups. Values
are means and SEM
Variable

Statin Group (N=8)

Placebo Group (N=9)

*Time to Exhaustion

36.05 ± 0.44

37.64 ± 0.38

Standard Deviation

1.249

1.133

Effect Size

r=0.55; d=1.33

P-value

0.014

Difference in mean

1.59

*Time to exhaustion values are presented in minutes
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Table 4. Cholesterol data for both statin and placebo groups
Variable
Cholesterol (mg/dL)
Standard Deviation
Effect Size
P-value
Difference in mean

Statin Group (N=8)
73.17 ± 5.31
15.02
r=0.46; d=15.02
0.047
14.67

Values are mean±SEM.
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Placebo Group (N=9)
87.84 ± 4.30
12.91

APPENDIX B –LITERATURE REVIEW

1. Introduction
Statins, also known as 3-Hydroxy-3-methylglutaryl coenzyme A (HMG-CoA)
reductase inhibitors, are a class of cholesterol-lowering drugs. Statins have been shown
to be very effective in reducing elevated levels of serum cholesterol and are well tolerated
by human beings (35). Due to their effectiveness and tolerance, statins are widely used
all over the world. The number of people purchasing statins almost doubled from 15.8
million in the year 2000 to 29.7 million by the year 2005 according to a U.S. medical
expenditure panel survey in 2008 (49). In the year 2011, statin prescriptions totaled
almost one million in the United Kingdom on a weekly basis (59).
Statins work by acting as inhibitors of the cholesterol pathway, specifically by
competing with HMG-CoA for the catalytic site of its reductase (39) . As a result, a
competitive inhibition occurs in the mevalonate pathway, a precursor molecule for the
synthesis of cholesterol and various other molecules (39). Potential side effects of statins
include skeletal muscle myopathy, which can range from mild complaints such as
weakness, and myalgia, to more serious conditions such as rhabdomyolysis and renal
failure (48). Such complications can possibly compromise medication compliance and
quality of life for certain statin users (55). It is not understood exactly how the statin
mechanism works (6), however, the prevalence of myopathy increases dramatically
among statin users that also exercise according to Sirvent et al. (57). Such trends indicate
that muscle performance may be affected. The effects of exercise and performance have
not been carefully examined among statin users (55). This brief literature review will
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provide an introduction to statins and their effects, with a focus on exercise and
performance.
2. Background
Cholesterol and Cardiovascular Health
A significant percentage of adults throughout the world have high levels of serum
cholesterol, which can lead to coronary heart disease (CHD). It is recommended that a
balanced approach consisting of proper diet, exercise, and supplementation/medication (if
required) is necessary to lower the risk of CHD (18). Major causes of heart-related issues
such as CHD has been associated with elevated levels of serum low-density lipoprotein
cholesterol (LDL-C) and decreased levels of serum high-density lipoprotein cholesterol
(HDL-C) (31, 43). Results from the National Health and Nutrition Examination Survey
(NHANES) indicate that among adults aged 20 years and older, 21% have elevated levels
of serum LDL-C (30). Research has shown that an extensive reduction of serum LDL-C
correlates with a lower risk for CHD (17, 26, 43). It is recommended that the general
population maintain serum LDL-C levels within the recommended limits (<100mg/dL) in
order to reduce the risk for CHD, and improve cardiovascular health and longevity.
Statins
Statins (3-hydroxy-3-methylglutaryl coenzyme A [HMG-CoA] reductase
inhibitor) are the type of drugs that have been shown to have the highest reduction
potential of the serum LDL-C concentration (39). By reducing serum LDL-C
concentration, statins have the capability to reduce cardiovascular risk factors associated
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with CHD. As of 2005, Statins were available in 6 different forms and known by a
variety of trade names: Atorvastatin (Lipitor), Fluvastatin (Lescol), Lovastatin (Mevacor,
Altoprev), Pravastatin (Pravachol), Rosuvastatin (Crestor) and Simvastatin (Zocor) (57).
Lovastatin, Pravastatin and Simvastatin are all fungal derivatives and share the same
dronaphthalene ring structure, and Simvastatin is a semi-synthethic methylated analogue
of Lovastatin, while Atorvastatin and Fluvastatin are all fully synthetic (2). According to
the annual report from Pfizer, Atorvastatin (Lipitor) was the top selling pharmaceutical in
the world in 2008 with sales worth $12.4 billion. Another class of statins, Cerivastatin
(Baycol), was voluntarily withdrawn from the worldwide market in 2001 (37) due to
reports of fatal rhabdomyolysis, as well as 52 deaths that were associated with kidney
failure (22). Regardless of the various nomenclatures, the primary goal of all statin
therapy is to decrease total and LDL-C concentrations.
Role of Statin in the Mevalonate Pathway
The synthesis of cholesterol requires several steps in the mevalonate pathway.
The enzyme HMG-CoA reductase is required for the conversion of HMG-CoA into
mevalonate (34). Statins work as competitive inhibitors and specifically compete with
the catalytic sites of HMG-CoA in the hepatic cells of the liver. The competition inhibits
the conversion of HMG-CoA into mevalonate, which serves as a precursor molecule for
the synthesis of cholesterol and other molecules such as the isoprenoids, farnesyl, and
geranyl pyrophosphates (39). As these precursor molecules are inhibited, the rate
limiting step in cholesterol biosynthesis is inhibited as well as a result, which results in a
reduction of plasma LDL-C levels (17).
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Synthesis of Cholesterol and Mechanism
According to Morales-Villegas et al. (39), every LDL macromolecule in the
human body contains molecules of cholesteryl ester and it can be as high as 1,500. These
molecules enter the cells through the existence of specially marked LDL receptors, which
are made up of glycoproteins that contain five domains that are embedded in the
structures of the cell membrane formed by clathrin protein called “clathrin-coated pits”
(39). An endocytic vesicle (endosome) is formed after the cell surface receptors that are
bound for endocytosis gather at the clathrin-coated pits and LDL cholesterol is scooped
up by the receptor (39). As the pH level lowers, the endosome allows the LDL receptor
to leave the endosome and return to the cell membrane inside the cell, which allows LDL
to be transferred from the endosomes to the lysosomes (39). Both lipids as well as
apoproteins are hydrolyzed into nonesterified cholesterol and amino acids, and due to the
hydrophobic nature of the nonesterified cholesterol, they are unable to move freely within
the cell cytoplasm (39). The LDL receptor is recycled in the cell and makes more than
100 cycles during its average 20-hr life cycle. By inhibiting the HMG-CoA reductase,
statins eventually reduce concentrations of cholesterol in the serum by reducing the
synthesis of cholesterol (39).
Benefits of Exercise related to cholesterol reduction
It has been well established that regular exercise and physical activity have
numerous beneficial effects on the cardiovascular system (32), and decrease the incidence
of mortality from cardiovascular disease (38). Results from a 20-year longitudinal study
on the effects of exercise on lipid profile has shown significantly improved markers of
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HDL-C, LDL-C and HDL/LDL ratio among middle aged adults (53). Participating in as
little as three hours per week of intense physical activity has been shown to lower risk of
myocardial infarction by as much as 22% among men (9). Physical activity has also been
shown to reduce blood pressure in adults with high blood pressure, and improve insulin
resistance and glucose tolerance (60). Furthermore, in addition to the beneficial effects
on cardiovascular health, exercise has also shown to improve psychological well-being,
body mass index, muscular strength, endurance, and performance among a myriad of
other benefits (12, 20).
3. Statins, Exercise and Performance
Statins and Exercise Performance
The literature pool addressing the interactions of statin treatment and exercise
performance is very limited. There has been a recent surge in interest in this particular
area as evidenced by several current and ongoing studies (45, 55, 58). Results from a
longitudinal study conducted by Scott et al. (45), suggests that statin therapy may be
associated with greater declines in strength and muscle quality, and greater increases in
falls risk in the population of community-dwelling older adults (45). This group noted
that the subjects that ceased statin use experienced a significant smaller decrease in leg
strength and leg muscle quality (LMQ) over 2.6 years compared to those subjects that
continued statin treatment (45). However, a study by Traustadottir et al., in 2008 showed
that high-dose statin did not impair exercise capacity among older adults (58). This
group looked at maximal oxygen consumption, aerobic endurance, muscular power and
muscular endurance pre and post 12 weeks of Simvastatin treatment and noted no
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significant changes in exercise capacity or performance (58). On the other hand, a study
on professional athletes by Sinzinger and O’Grady on various statin treatments over an 8
year period concluded that only 20% of top sports performers were able to tolerate statin
treatment without any side effects or decline in performance (46). While the observed
conclusions are contributory to research, the results are mixed and association between
statin use and muscle performance require further examination given the high prevalence
of statin users (45).
Statins and Exercise
The benefit of statin therapy is complicated by the common finding that exercise
seems to increase the risk for statin-induced myopathy (15). In clinical practice, it has
been reported that the incidence of muscle pain increases with the level of physical
activity, with a great number of patients avoiding moderate exertion during everyday
activities (5) and it is believed that statins may adversely affect the muscle’s ability to
appropriately respond to physical exertion (54). This presents a dilemma as statin users
should not have to compromise the benefits of exercise and a healthy lifestyle (35).
Franc et al. (19) suggests that muscular problems occur more frequently during and after
exercise in statin therapy patients and several case reports and studies seem to support
this (29, 46). Early research has shown that exercise and statin therapy independently
increase creatine kinase (CK) levels, however the interaction between the two had not
been examined until the past decade (35). Using a double-blind, placebo-controlled
design, Thompson and colleague (56) showed that exercise in combination with statin
produces a greater CK elevation, indicating exercise-induced skeletal muscle injury.
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Based on the type of exercise performed, their study also suggests that eccentric exercise
is more likely to induce myopathy. A recent study by Kearns et al. investigated the
effects of statin dosage and serum CK levels in response to a single bout of downhill
treadmill exercise, and showed that the elevation in CK levels after an exercise bout may
not be related to the prescribed statin dosage, as exercise can increase CK levels with
even low dose statin therapy (29). While both studies provide valuable information
regarding statins, the utilization of serum CK as a marker of muscle damage may
underestimate the prevalence or the severity of statin-associated myopathy, especially in
combination with exercise (35). It is evident that a large portion of the existing literature
is based on blood markers of muscle damage with mixed results and it is important to
note the distinction between an exacerbation of statin-associated myopathy by exercise
and an exacerbation of exercise-induced damage by statins (35). Identification of the
circumstances in which statin exacerbates muscle function and the mechanisms through
which these effects are mediated are needed in order to appreciate the full benefits of
both statin therapy and physical activity for optimal health and performance. Future
studies that examine the interaction of statin and exercise through more dependable
measures are necessary.
4. Possible Factors and Mechanism Affecting Performance
Myopathy
Although statins are a relatively safe family of drugs, it does however carry a
significantly elevated risk of myopathy, which can range from muscle weakness, aches,
and fatigue, to rhabdomyolysis (35). According to Cotter et al. myopathies can range
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from 1% to 10%, while cases of rhabdomyolysis are rare, and it is estimated to affect
0.1% of all statin users (15). While the risk of complications due to statin therapy is
pretty low, there is a chance that cases of statin-induced myopathy can possibly go
undetected. It is believed that as many as 25% of statin users who experience myalgia
can unknowingly dismiss the symptoms of myopathy along with their physicians (46).
Previous studies have shown that the risk of statin-induced myopathy can increase in a
dose-dependent manner (24), while as increased statin doses decrease LDL-C and
cardiovascular risk (7). Overall, the primary issue is that it seems that lipid profiles and
muscle functions clearly conflict with each other, as physician recommended doses favor
ideal lipid profile rather than ideal muscle function (35).
Possible Mechanism of Statin-induced Myopathy
The exact mechanism behind statin-induced myopathy is not clear, and it is
unknown whether pathways that are responsible for myopathy in sedentary individuals
are also the pathways responsible for myopathy exacerbated with exercise (35). Various
studies point to many possible contributing factors and it could be a combination of
several components that could be responsible for myopathy. Studies have shown that
statins can induce apoptosis in various types of cells, such as myotubes, myoblasts, and
mature skeletal muscle cells in both humans and animals (28), all of which can possibly
affect muscle performance.
Membrane Fluidity
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Reduced cholesterol content due to statins can affect membrane fluidity (63),
which could be another possible contributor to statin-induced myopathy, as muscles can
be exposed to high levels of stretch during exercise and the risk of myopathy would
significantly increase. Since membrane composition and fluidity has not been examined
under the additional stress of exercise, it is possible that the increased mechanical load of
stretch imposed on the muscle fiber with exercise can show how shifts in membrane
composition and fluidity could lead to damage (35).
Mitochondrial Dysfunction
Studies have suggested that statin-induced myopathy could also be a result of
mitochondrial dysfunction (13, 51). The mitochondria plays a crucial role in cellular
metabolism and energy production, hence any defect in mitochondrial function could
possibly affect muscle function and performance. Exercise dramatically increases
oxygen consumption and, consequently the activity of muscle metabolic pathways, of
which mitochondria are an essential component. This presents an obvious route through
which exercise may exacerbate statin-associated myopathy. However, this possibility has
been examined only indirectly in current research, with conflicting results (35).
5. Markers
Time to Exhaustion
Time to exhaustion has been used as a marker for performance in various human
and animal studies. Researchers in one particular study, examining the effects of the
glycemic index of foods on performance, had subjects cycle at various intensities
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corresponding to a particular VO₂max and recorded the time to exhaustion as a marker
for performance (27). Furthermore, studies investigating the role of fitness and exercise
under heat stress conditions have used time to exhaustion, as based on maximal oxygen
uptake, as an indicator of performance (42). Similarly, many animal studies have also
used time to exhaustion as an indicator of performance. Takeda and colleagues (50) used
an animal model to examine the effects of citrulline on fatigue and exercise performance
in mice. Their study involved a swimming exercise protocol, where the mice were
subjected to exhaustive swimming with a 5% body weight load and time to exhaustion
was noted as the primary marker. Olfert et al. (41) used a protocol where aerobic
performance was evaluated by measuring the maximal running speed and time to
exhaustion in a study investigating exercise-induced skeletal muscle angiogenesis in
mice. In this particular study, the end-of-test criteria used to determine exhaustion was
defined by the point where the mouse was no longer able to maintain its normal running
position on the treadmill and if the mouse was shocked for five seconds or more in
contact with the shock grid (41). Based on the above literature, it is evident that time to
exhaustion can serve as a valid measure of performance.
Markers of Skeletal Muscle Injury
Cases have shown that a decline in muscle performance due to myopathy is
accompanied by an increase in CK levels (10, 16, 21). Elevated levels of creatine kinase
can indicate muscle injury and is often as an indirect indicator of myopathy in research
and medicine (11). Creatine kinase levels typically rise within 12 hours after muscle
injury, peaks during 1-3 days and declines after 3-5 days after the cessation of muscle
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injury (61). Creatine kinase levels above 5,000 u/L can possibly lead to renal failure, as
renal glomerular filtrate can precipitate and cause renal tubular obstruction resulting in
kidney damage (2). However, CK levels can also be elevated without the presence of a
muscle injury. A study performed by Gojanovic et al. (23) noted a significant increase in
CK levels in 25% of the subjects after whole-body vibration training in healthy human
subjects. Gojanovic further states that such elevation is transient and harmless and can
possibly be wrongly attributed to statin-induced myopathy (23). Markhsous et al. (33)
performed a study on the effects of deep muscle tissue injury in Sprague Dawley rats and
noted a significant increase in troponin levels, especially after 36-48 hours postcompression event. Their results demonstrated a sensitive response of troponin levels to
muscle injury and the rapid increase of concentrations of troponin can indicate severe
deep muscle injury (33). It is evident that while CK levels can possibly indicate muscle
injury, the utilization of CK solely as a marker of muscle damage may underestimate the
prevalence of the severity of statin-associated myopathy (35). Therefore, measurements
in troponin levels may potentially serve as a better marker as it is more sensitive to
skeletal muscle breakdown (3).
6. Conclusion
A vast number of people around the world suffer from high levels of cholesterol,
which can lead to coronary heart disease. A combination of healthy diet, regular exercise
and medication is often necessary to control elevated cholesterol. It is evident that statin
treatment has been shown to be very effective in reducing elevated levels of serum
cholesterol. A majority of human beings are able to tolerate statin therapy. The number
of statin prescriptions nearby doubled within the last decade as statins have become one
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of the most commonly used drug in the world. While statins have been shown to be very
effective, potential side effects can possibly include skeletal muscle myopathy, pain,
weakness, or even rhabdomyolysis and renal failure (48). As a result of this
complication, medication compliance and quality of life can be affected for many statin
users (55). The exact mechanism of statin-induced myopathy is not well understood (6).
However, statin users that also exercise have the potential of increased prevalence of
myopathy (57). Trends like these suggest that muscle performance can be possibly
affected.
The effects of statin on exercise performance among statin users has not been
carefully explored, and the relatively sparse data on this subject has been somewhat
inconsistent (55). It has been well established that regular exercise and physical activity
has been shown to have numerous beneficial effects on the cardiovascular system (32),
and decrease the incidence of mortality from cardiovascular disease (38). Therefore, it is
important that exercise performance is not compromised among statin users so these
individuals can maximize their benefits.
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